Foundation’s Oral Therapies Initiative Marks Five Years of Advocacy and Research

Over the past five years, an increasing number of lymphoma and chronic lymphocytic leukemia (CLL) patients receive their chemotherapy not from intravenous (IV) treatments administered in a hospital or clinic, but via a pill, taken at home on a regular basis, similar to prescriptions for many other health conditions. These oral therapies have become a more standard part of patient care, and for a growing number of patients, oral therapies are their only option. However, issues unique to their use have become concerns for clinicians and researchers in the lymphoma community.

The Lymphoma Research Foundation’s Oral Therapies Initiative, founded in 2015 to explore these concerns, recently marked five years of advocacy on these issues with a June 2019 publication in *Leukemia & Lymphoma*, exploring current research into the issue of adherence in oral therapies and making recommendations for future research questions that should be explored to truly understand the effect of various real-world concerns and influences on a lymphoma patient’s successful adherence to a treatment plan involving oral chemotherapy. This publication is just the latest effort by the Oral Therapies Steering Committee, led by Foundation Scientific Advisory Board members Jonathan Friedberg, MD, MMSc, of Wilmot Cancer Institute, University of Rochester, and Michael Williams, MD, ScM of the University of Virginia Cancer Center, to advocate for greater exploration and research into oral therapies in lymphoma, through both scientific meetings, editorials, and academic publications.

“Oral therapy for lymphoma and CLL has become an important option for many patients,” said Dr. Williams, “The appeal of prolonged remission, the perception that it is more convenient and may decrease office visits, and having a greater sense of control over one’s own care are all appealing. However, with this shift, all of us involved in lymphoma patient care must pay attention to the efficacy, value, and cost, as well as the convenience of and adherence to oral therapies.”

[CONTINUED ON PAGE 3]
Dear LRF Friends and Supporters,

The Lymphoma Research Foundation’s research portfolio encompasses not just the grants we fund, but a number of scientific workshops and initiatives designed to bring attention to and encourage collaboration on important issues in lymphoma research and patient care, particularly those that are understudied or related to the quickly changing treatment landscape in lymphoma and chronic lymphocytic leukemia. In this issue of Research Report, we highlight several such programs, beginning with our cover article, an overview of the first five years of our Oral Therapies in Lymphoma Initiative. This initiative, which recently published a paper in the academic journal *Leukemia & Lymphoma*, has raised awareness among the research community and beyond about the unique issues which affect patients who take oral agents for the treatment of their lymphoma.

This spring, the Foundation also hosted two first-of-their-kind scientific workshops on Marginal Zone Lymphoma and Adolescent/Young Adult Lymphomas, two areas of understudied research. A summary of both workshops begins on page 4. In addition, Foundation grantees, Scientific Advisory Board members, and other researchers with Foundation ties presented a number of studies at the American Society for Clinical Oncology (ASCO) Annual Meeting and International Conference on Malignant Lymphoma (ICML), both held in June 2019. Highlights from these presentations begin on page 6.

This edition of Research Report showcases the broader impact of the Foundation’s research portfolio beyond our annual grant funding. Thank you for all you do in helping the Foundation advance innovative research and improve care for all who are impacted by a lymphoma diagnosis.

Sincerely,

Meghan Gutierrez  
Chief Executive Officer

Team LRF Spotlight: Team Kweit

Lewis Kweit, of New York, NY founded Team Kweit to participate in the New York Lymphoma Walk in memory of his wife, Karen. For the 2019 New York Walk, Team Kweit raised over $18,000, bringing their two year total to nearly $50,000, and raising the most funds of any NY Walk team in both 2018 and 2019.

In recognition of Team Kweit’s efforts, Lewis and Team Kweit received the prestigious Founder’s Award at the 2019 New York Walk from Marnie Gordon, who created the Lymphoma Research Foundation’s New York Walk as a volunteer more than twenty years ago.

The 2019 Lymphoma Walk season will conclude with the Chicago Walk on August 4 and the Arizona Walk in Phoenix on October 20. For more information, visit lymphoma.org/teamlrf.

Lewis Kweit (R), receives the Founder’s Award from Marnie Gordon at the 2019 New York Lymphoma Walk.
History of the Oral Therapies Initiative

In 2013, the U.S. Federal Drug Administration (FDA) approved oral chemotherapy agents lenalidomide (Revlimid) and ibrutinib (Imbruvica) for relapsed mantle cell lymphoma, kickstarting a new era in which oral therapies for lymphoma and other cancers have become increasingly standard therapies. In the five years following lenalidomide’s approval, six oral chemotherapies have been approved for a range of lymphoma subtypes and seven additional therapies are being investigated in clinical trials for lymphoma.

Although it was hoped that the advent of oral therapies to treat cancer would ease some of the stress, time, and financial burden of the frequent trips to the hospital required by traditional chemotherapy, clinicians and researchers began to have concerns around the real-world use of these therapies by patients. In response to these concerns, the Lymphoma Research Foundation hosted a first-of-its-kind science and policy workshop, Oral Therapies in Lymphoma, in Washington, D.C., in September 2015. The workshop, which included clinicians, researchers, pharmaceutical industry representatives, patient advocates, and members of Congress, sought to identify the specific challenges facing the scientific and patient communities related to the development, optimization, treatment adherence, and access to lymphoma oral therapies.

In order to ensure the scientific rigor of the workshop, LRF assembled an Oral Therapies Steering Committee from members of its Scientific Advisory Board. In the five years since that initial workshop, the Committee has continued its efforts to explore the changing nature of lymphoma and chronic lymphocytic leukemia treatment due to oral therapies, and advocate for further research into how their use impacts patient care.

The Steering Committee’s efforts led to a second workshop, Adherence and Oral Therapies in Lymphoma and CLL, hosted in New York City in October 2017, which focused on the complexities of patient nonadherence to oral anti-cancer therapy, including concerns around cost and duration of therapy, misconceptions about the need to continuously take therapy when a patient is asymptomatic, and the impact of comorbidities (other health issues) on the effectiveness of oral therapies due to drug-drug interactions. The workshop also explored how clinicians in diseases that also rely on oral therapies (such as HIV and leukemia) have addressed these issues, and how their models might be adapted for lymphoma.

Publications and Future Goals

In June 2019, Dr. Friedberg and other members of the Oral Therapies Initiative, including SAB member Christopher R. Flowers, MD, of Winship Cancer Institute, Emory University, and Mary Lou Somma, representing the Foundation’s Scientific and Research Programs, published a paper “Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs,” in the academic journal Leukemia & Lymphoma.

The paper offers an overview of the existing research on adherence to oral medications. This research suggests several key influences on oral therapy adherence, including the negative impacts of complex treatment regimens (for example, plans which require several different therapies or a change in dose levels), the rising cost of treatment and insurance co-payments, patients being unable to obtain their lymphoma medication from their regular pharmacy, as well as the positive impact of educational programs for patients and other interventions, such as automatic prompts to take medicine and monitored dosing boxes.

The authors note that overall data available on oral adherence specific to lymphoma patients was limited, and identified research questions that could be pursued to better understand this issue, including addressing the influence of age, gender, health literacy, pre-existing patient perceptions of oral

[CONTINUED ON PAGE 10]
The Lymphoma Research Foundation’s scientific programs have long sought to promote discussion around pressing issues in research and patient care. In Spring 2019, two new scientific workshops addressed issues in marginal zone lymphoma (MZL) and adolescent/young adult (AYA) lymphomas patient populations.

The Marginal Zone Lymphoma Scientific Workshop, one of the first scientific workshops in the United States to focus exclusively on this rare group of B-cell non-Hodgkin lymphomas, took place April 17 and 18 in New York City. Held in partnership with the International Extranodal Lymphoma Study Group (IELSG), a leader of MZL research in Europe, the workshop brought together an international group of researchers, clinicians, and industry representatives who specialize in MZL, which is in actuality a group of several lymphoma subtypes including mucosa-associated lymphoid tissue (MALT) lymphomas, and forms which occur both in the lymph nodes (nodal) and without (extranodal). These subtypes include lymphomas which occur in the skin (cutaneous), eyes (ocular), salivary glands, and gastric system, making it difficult for a one-size-fits-all treatment approach. Additionally, the small number of MZL patients diagnosed each year complicates researchers’ ability to enroll enough patients on standard clinical trials to get statistically significant results.

The workshop, led by Steering Committee Co-Chairs and LRF Scientific Advisory Board members Morton Coleman, MD of Weill Cornell Medicine, and Thomas M. Habermann, MD, of Mayo Clinic, Rochester, presented an opportunity for the group of U.S. and European investigators to share data and hypotheses, as well as to discuss new potential collaborations with the potential to advance the field with large-scale innovative study. The final afternoon of the two-day workshop featured an in-depth discussion of unmet needs in MZL, focusing on four key thematic areas: pathophysiology, etiology and natural history; therapeutic approaches; clinical trial and study design; and diagnosis, assessment, and response. Publications covering the proceedings and ideas from the workshop are currently in process.

“The Lymphoma Research Foundation’s Marginal Zone Lymphoma Scientific Workshop gave researchers from six countries the opportunity to do something we rarely get to do – focus exclusively on marginal zone lymphoma and ways we can drive the field forward for this unique group of diseases,” said Dr. Habermann, who was also LRF’s Scientific Advisory Board Chair at the time of the meeting. “The interactions during the meeting were phenomenal at all levels. It is my hope that the conversations we began at this meeting will lead to collaborations that will in turn lead to a deeper understanding of this complex group of disorders along with more and better treatment options for MZL patients.”

The Adolescent/Young Adult Lymphoma Scientific Workshop, held May 14 and 15 in Chicago, marked the expansion of LRF’s AYA Lymphoma Initiative, founded in 2015 with support from The Paul Foundation to address research issues unique to adolescent and young adult lymphoma patients, defined by the National Institutes of Health as patients aged 15 to 39. Building on the success of a one-day symposium hosted by the Foundation in September 2015, which subsequently resulted in a publication in Blood Advances, the 2019 AYA Scientific Workshop brought pediatric and adult oncologists and lymphoma researchers, regulatory officials, and industry representatives together for a two-day workshop examining the biological, clinical, epidemiological, and health services issues that cause unique complications in both caring for and conducting research on this patient population.

Under the direction of AYA Lymphoma Steering Committee Co-Chairs Kara Kelly, MD of Oishei Children’s Hospital and Roswell Park Cancer Institute, and Dr. Habermann, the workshop assembled six panels to discuss the differences between pediatric and adult oncology treatment strategies, biological factors unique to AYA lymphomas, existing clinical trials focused on AYA patients and strategies for developing new trials, how databases and real-world data can be utilized to gain greater insight into AYA patient outcomes, and survivorship issues for a patient group which may live post-lymphoma for several
decades.

The workshop concluded with breakout sessions focused on research topics important to the understanding of AYA lymphoma, including biology and epidemiology, future drug development, care delivery and outcomes, and survivorship. Participants in each breakout session identified key themes, unmet needs, and research priorities for their topic before reconvening to discuss their ideas with the full group. The Foundation and the AYA Lymphoma Steering Committee will take these ideas into account as they develop future programming and projects for the AYA Lymphoma Initiative.

“The Lymphoma Research Foundation’s Adolescent/Young Adult Lymphoma Scientific Workshop brought together pediatric and adult oncologists who get too few opportunities to share their knowledge with each other,” said Dr. Kelly. “The feedback we’ve received from the researchers in attendance has been incredibly positive and we are excited to advance the field of AYA lymphoma research.”

Patients and other stakeholders interested in receiving updates when publications from these workshops are available should visit lymphoma.org/subscribe to sign up for AYA and MZL specific email updates. If you are already subscribed to LRF you may add AYA and/or MZL updates to your email preferences at that link.
News from the Field: Summer 2019 Scientific Conferences

Scientific conferences offer an opportunity for researchers to share the findings of their latest studies and discuss their impact on patient care with other researchers from around the world. In June 2019, two major conferences, one which encompasses all oncology and one focused exclusively on lymphoma, featured a number of presentations from Lymphoma Research Foundation grantees, Scientific Advisory Board (SAB) members and research consultants. Highlights of those meetings are covered here.

ASCO

The Annual Meeting of the American Society of Clinical Oncology (ASCO) is one of the largest annual oncology conferences in the world, assembling clinical researchers from across all types of cancer, including lymphoma and chronic lymphocytic leukemia.

The TRANSCEND CLL 004 trial, which investigated new CD19 CAR T-cell therapy liso-cel (lisocabtagene maraleucel (liso-cel)) in relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), was presented by Deborah Stephens, DO, of University of Utah, Huntsman Cancer Institute. Dr. Stephens, a 2014 LRF Scholar, noted that in this small scale trial, thirteen of the fifteen evaluable patients achieved a response to treatment (87 percent), with seven patients achieving a complete remission. Ten patients (67 percent) had undetectable minimal residual disease (MRD) within 30 days of their treatment, a measure of remaining cancer cells that can indicate a risk for relapse. These results indicate liso-cel may be an effective treatment for CLL/SLL patients who relapse following ibrutinib. The trial is still ongoing and enrolling new patients.

TRANSCEND CLL 004 data was also presented at ICML by Tanya Siddiqi, MD, of City of Hope, who has assisted the Foundation in the development of patient education materials. LRF grantee Jacob Soumerai, MD, of Massachusetts General Hospital, was also an author on this study.

Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, a 2015 LRF Scholar, presented results of the Smart Start trial, a first-of-its-kind study investigating a non-chemotherapy treatment regimen to kick off treatment for patients with non-germinal center diffuse large B-cell lymphoma (DLBCL). Sixty enrolled patients received a combination of targeted therapies rituximab (Rituxan), lenalidomide (Revlimid) and ibrutinib (Imbruvica) for two cycles (RLI), prior to a combination of those agents with chemotherapy. Dr. Westin and his colleagues hoped beginning with a chemotherapy-free regimen would improve outcomes and reduce side effects. With 52 evaluable patients, the overall response rate after the RLI cycles was 84.6 percent (44 patients), and the complete response rate was 38.5 percent (20 patients). Dr. Westin further noted that one patient who achieved complete response opted not to continue to the chemotherapy regimen and remains relapse free 18 months after treatment. Additional studies evaluating more cycles of RLI with less chemotherapy are planned.

This study was also presented at ICML by Dr. Westin. The ASCO abstract included contributions from former Scientific Advisory Board member Nathan Fowler, MD, also of MD Anderson Cancer Center.

The ECHELON-2 trial, an international study exploring the treatment regimen A+CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone) versus CHOP (cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone) in frontline treatment for peripheral T-cell lymphoma (PTCL) patients with disease positive for the biomarker CD30, was presented by Ranjana Advani, MD, of Stanford University, an LRF Scientific Advisory Board member. After seeing significantly improved rates for complete response (68 percent A+CHP to 56 percent CHOP) and objective response (83 percent A+CHP to 72 percent CHOP), Dr. Advani and her collaborators examined whether there was a difference between level of CD30 expression and the response to A+CHP, noting that in subtypes like systemic anaplastic large-cell lymphoma (sALCL) high CD30 expression is universal, but that the expression level can vary among patients with other PTCL subtypes. Although all patients with CD30 expression greater than 10 percent were eligible for the ECHELON-2 study, researchers found most angioimmunoblastic T-cell lymphoma (AITL) patients had CD30 expression levels between 10 and 30 percent, while patients with PTCL not otherwise specified were evenly distributed from levels between 10 and 100 percent. However, researchers found that CD30 expression was not predictive of response, indicating the significant results for A+CHP will be effective for a...
wide number of patients with CD30+ PTCL. Researchers noted that given the lack of relationship found here, patients with less than 10 percent CD30+ should also be evaluated.

This study was also presented at ICML by Tim Illidge, PhD, of the University of Manchester. The ASCO abstract included contributions from SAB members Nancy Bartlett, MD, of Washington University in Saint Louis, Steven Horwitz, MD, of Memorial Sloan Kettering, and Owen O’Connor, MD, PhD, of Columbia University Medical Center.

ICML

The International Conference on Malignant Lymphoma (ICML), held biannually in Lugano, Switzerland, assembles international experts on the treatment of lymphoma for presentations and in-depth discussion of the latest research as well as pressing issues in the research and treatment of lymphoma and chronic lymphocytic leukemia. At the 2019 ICML, eight research sessions and three case discussion sessions were chaired by Foundation Scientific Advisory Board members, with an additional two sessions chaired by former SAB members.

Additionally SAB member Ari Melnick, MD of Weill Cornell Medicine, was invited to give the Gianni Bonadonna Memorial Lecture as part of the keynote presentations. In his talk “Precision Epigenetic Therapy for B-Cell Lymphoma,” Dr. Melnick discussed common mutations found in DLBCL and follicular lymphoma (FL), and the therapies in development to address their effects on lymphoma disease progression, both as individual targeted agents and as adjunct to immunotherapy. Dr. Melnick was introduced by the Bonadonna lecturer from 2017, Margaret Shipp, MD, of Dana-Farber Cancer Institute, also a Foundation SAB member.

A number of grantees and SAB members were also invited to give oral presentations of their research, with several highlights below.

Foundation SAB member Ranjana Advani, MD, of Stanford University, presented initial results of a first-in-class therapy for relapsed/refractory non-Hodgkin lymphoma. The therapy, Hu5F9-G4 (5F9) is an antibody targeting CD47, a protein which, when expressed by cancer cells, serves as what the researchers call a “don’t eat me” signal, allowing the cells to grow without being attacked by the immune system. Dr. Advani and her colleagues tested 5F9 in combination with rituximab in 22 patients with DLBCL and FL, 90 percent of whom had relapsed or not responded to rituximab alone. The overall response rate was 50 percent, with 32 percent achieving complete response, and the majority of patients experiencing only low-grade side effects. Researchers also reported that 90 percent of patients who responded were still in response, including one patient who had maintained their response without disease progression for over thirteen months. The researchers noted the 5F9-rituximab combination appeared to be both effective and well tolerated, and added that larger scale trials are currently ongoing in both indolent lymphoma and DLBCL.

This study was also presented at ASCO by Dr. Advani and at the annual meeting of the European Hematology Association (EHA) by Dr. Mark Roschewski, MD, of the National Cancer Institute. The ICML abstract included contributions from SAB members Nancy Bartlett, MD, of Washington University in Saint Louis, Ann LaCasce, MD, of Dana-Farber Cancer Institute, and Sonali M. Smith, MD, of The University of Chicago, as well as past LRF grantee Leslie Poppelwell, MD, of City of Hope, and MCL Consortium member Ian Flinn, MD, PhD, of Sarah Cannon Research Institute.

Another new therapy being tested in combination with rituximab was presented by Andrew D. Zelenetz, MD, PhD of Memorial Sloan Kettering Cancer Center, incoming Chair of the Foundation’s Scientific Advisory Board. ME-401, an inhibitor of the phosphoinositide 3 kinase (PI3k), was evaluated in an early phase study of patients with relapsed and refractory B-cell malignancies – Dr. Zelenetz’s presentation focused on results in patients with FL and CLL/SLL. Of the 43 evaluable patients in FL, 33 (77 percent) achieved an objective response to the [CONTINUED ON PAGE 9]
The Lymphoma Research Foundation’s signature professional education program series, “Lymphoma Rounds,” provides a forum for local healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Lymphoma Rounds launched in 2008 in Chicago and is currently held in eight markets across the U.S. including Chicago, Los Angeles, New England, New York, Philadelphia, San Francisco, Seattle, and Washington, D.C. – with each market meeting multiple times a year. Participants in the program receive Continuing Medical Education (CME) credits, allowing them to keep their expertise in lymphoma treatment up-to-date.

In April 2019, the Foundation partnered with the academic journal Leukemia & Lymphoma to feature select cases from LRF Lymphoma Rounds’ programs. Each published case is reviewed by Morton Coleman, MD, and Koen van Besien, MD, PhD, of Weill Cornell Medicine, both Steering Committee members of the New York Lymphoma Rounds program. Dr. Coleman is also a member of LRF’s Scientific Advisory Board and Board of Directors, Chair of the Foundation’s Medical Affiliates Board, and Lymphoma Rounds founder; Dr. van Besien is a long-time LRF Mantle Cell Consortium member and a current editor-in-chief of Leukemia & Lymphoma. The first Lymphoma Rounds case was published in the 18 April 2019 digital issue and focused on the treatment of refractory T-cell prolymphocytic leukemia (T-PLL), a rare T-cell lymphoma. Presented initially at New York Lymphoma Rounds by Alexandra Gomez-Arteaga, MD, a fellow at Weill Cornell Medicine, and Dr. van Besien, the published case study also featured contributions from Foundation SAB member Steven Horwitz, MD, of Memorial Sloan Kettering Cancer Center. Additional case studies will be published throughout the year.

“As attendance at the Foundation’s Lymphoma Rounds programs steadily increases, the Lymphoma Research Foundation continues to identify opportunities to expand the reach of these programs beyond their host cities,” said Piper Harmon, Senior Manager of Professional Education Programs. “The Foundation’s partnership with Leukemia & Lymphoma not only allows the cases discussed at Lymphoma Rounds, often involving rare lymphomas or unusual clinical presentations, to be made available to a wider audience, but offers an opportunity to improve care for lymphoma patients.”

For more information about Lymphoma Rounds and other resources for healthcare professionals, visit lymphoma.org/professionaled.
ME-401+rituximab combination, and all 11 CLL/SLL patients (100 percent) responded. Additionally, Dr. Zelenetz and his collaborators noted that patients started on an initial daily continuous schedule of the therapy and then switched to an intermittent schedule in cycle three to reduce toxicity, but that patients whose disease progressed while on the intermittent schedule stopped progressing by going back to a continuous schedule. An international study is currently enrolling patients with relapsed/refractory FL that will test different schedules for switching between continuous and intermittent schedules in order to determine the most effective schedule. A patient's disease progression was understudied. Dr. Strati and his colleagues noted that these data suggest pre-treatment SUV could be used to identify patients that may need the more aggressive course of therapy, but that further studies to confirm these findings are needed.

This abstract also included contributions from current LRF grantee Jacob Soumerai, MD, of Massachusetts General Hospital, and past grantees John Pagel, MD of Swedish Cancer Institute.

Paolo Strati, MD, of MD Anderson Cancer Center, a 2019 LRF Scholar, presented a retrospective analysis on the value of pre-treatment positron emission tomography (PET) scans for patients with FL receiving their initial therapy. Dr. Strati noted that PET is currently recommended for FL patients for initial staging, evaluation of potential transformation, and response assessment, but that the potential prognostic value of this pre-treatment scan was understudied. Dr. Strati and his colleagues looked at the records of 346 patients who received frontline rituximab based therapy at MD Anderson between 2001 and 2014, looking at the standardized uptake value (SUV), a measurement done in PET scans that helps indicate the amount of cancerous tissue in a patient’s body. The researchers found that patients whose pre-treatment scan showed an SUV of greater than eighteen had significantly shorter progression free survival and complete response rate when treated with a non R-CHOP regimen, but that those treated with R-CHOP had similar rates to patients with lower SUV. However they also found that patients in the greater than eighteen group had shorter overall survival regardless of the therapy given. Noting that R-CHOP is considered a more aggressive treatment than most standard non-R-CHOP therapies, Dr. Strati and his collaborators noted that these data suggest pre-treatment SUV could be used to identify patients that may need the more aggressive course of therapy, but that further studies to confirm these findings are needed.

This abstract also included contributions from current LRF grantee Jacob Soumerai, MD, of Massachusetts General Hospital, and past grantees John Pagel, MD of Swedish Cancer Institute.

Elise Chong, PhD, of the University of Pennsylvania, the Foundation’s 2019 Bruce D. Cheson, MD Postdoctoral Fellow, presented four-year follow-up results from a trial of CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) in relapsed and refractory DLBCL and FL. Dr. Chong noted that eligible patients enrolled in the study had no curative treatment options and a prognosis of less than two years survival at time of enrollment. With the median follow-up now at 49 months, 46 percent of the 24 DLBCL patients and 71 percent of the fifteen FL patients had a complete response. For patients who responded to treatment in either group, the median response duration (the point at which half of the patients have experienced disease progression) has not yet been reached, more than four years later. The patient with the longest follow-up period remains in remission from double-hit DLBCL at 60 months (five years) after their initial CAR-T therapy. Dr. Chong also noted that these results are the longest follow-up results reported to date for tisagenlecleucel in B-cell lymphomas and that for patients with few other options, CAR T-cell therapy continues to offer long-lasting results.

This trial also included contributions from former SAB member Nathan Fowler, MD, past LRF grantee Jason Westin, MD, and MCL Consortium members Jorge Romaguera, MD and Michael Wang, MD, all of MD Anderson Cancer Center.

Connie Batlevi, MD, PhD, of Memorial Sloan Kettering Cancer Center, a 2015 LRF Scholar, presented early clinical trial data of a second-generation chimeric antigen receptor (CAR) T cell therapy that targets not just the protein CD19, but a second commonly expressed protein, either C2D28 or 4-1 BB. Patients with relapsed or refractory lymphomas including DLBCL, FL, transformed FL, Waldenstrom macroglobulinemia, and CLL including Richter’s transformation were eligible to enroll in the study, which sought to evaluate the safety of these CAR T-cells and assess overall response rate. Twenty-seven patients were evaluable for response, with sixteen (59 percent) achieving a complete response; eight of these patients remain in complete response at a median of 169 days following therapy. Researchers noted no severe cytokine release syndrome and three patients with neurotoxicity, but no cerebral edema, indicating low occurrence of common severe side effects for CAR T-cell therapy. Dr. Batelvi and her colleagues indicated further studies of this second-generation CAR T-cell therapy are warranted to gauge if it is a significant improvement on existing therapies.

This trial also included contributions from SAB member Anas Younes, MD, and former grantees.
Oral Therapies Initiative

Oral Therapies
(CONTINUED FROM PAGE 3)

therapies prior to treatment, and patient-physician or other healthcare relationships on therapy adherence; the effect of logistical challenges such as drug-drug interactions from multiple health issues, visiting multiple pharmacies to fill prescriptions, and the increased cost of therapies when compared to traditional therapies; as well as identifying not only whether interventions and educational programs significantly alter adherence rates but which types of interventions are most effective.

“The not only is research into this field essential to enhance the experiences of lymphoma patients,” noted the authors in their conclusion, “but it could also apply to a wide range of cancers and diseases that may use oral treatments in the future.”

The Leukemia & Lymphoma article marks the fourth publication proceeding from the Oral Therapies Initiative, which also include:

- “Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL,” a June 2018 editorial in The ASCO Post from Drs. Williams and Friedberg, offering an overview of LRF’s efforts and advocating for the development of research and new care models to help patients maximize the benefits of this treatment.

In addition to the above publications, the Foundation has developed an Oral Agents in Lymphoma Fact Sheet to educate patients and caregivers on available oral therapies and factors to be aware of when one is prescribed. To download the fact sheet, visit lymphoma.org/oraltherapy. Healthcare professionals can also receive bulk orders of print materials free of charge via lymphoma.org/professionaled.

News from the Field
(CONTINUED FROM PAGE 9)

Maria Lia Palomba, and Renier Brentjens, MD, PhD, all of Memorial Sloan Kettering Cancer Center, as well as Craig Moskowitz, MD, of the University of Miami.

Results of a trial investigating the Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) in relapsed and refractory CLL were presented by Kerry Rogers, MD, of The Ohio State University. The trial focused on enrolling patients who had developed intolerance to ibrutinib (also a BTK inhibitor), suffering severe or persistent side effects, and whose disease progressed after discontinuing ibrutinib treatment. Sixty patients were treated, with an overall response rate of 72 percent. Moreover, at a median follow-up of 23 months, 62 percent of patients were able to remain on acalabrutinib, with the majority discontinuing due to progressive disease (thirteen percent); while ten percent of patients discontinued acalabrutinib due to adverse events researchers cited a recent paper noting that the majority of patients who discontinue ibrutinib do so due to intolerance. Dr. Rogers and her collaborators suggested acalabrutinib may be a safe and effective option for CLL patients who are intolerant to ibrutinib but whose disease responds well to BTK inhibition.

This abstract included contributions from SAB member Bruce D. Cheson, MD, FACP, FAAS of Georgetown University and former SAB member Thomas J. Kipps MD, MD, of the University of California San Diego.

For more News from the Field, visit lymphoma.org/newstype/research-news.
The Lymphoma Research Foundation’s volunteer Scientific Advisory Board, comprised of 45 world-renowned lymphoma experts, guides the Foundation’s research activities, seeking out the most innovative and promising lymphoma research projects for support.

Andrew D. Zelenetz, MD, PhD  
Chair  
Memorial Sloan Kettering Cancer Center  

Sonali M. Smith, MD  
Chair-Elect  
The University of Chicago  

Ranjana Advani, MD  
Stanford University School of Medicine  

Ash Alizadeh, MD, PhD  
Stanford University School of Medicine  

Stephen Ansell, MD, PhD  
Mayo Clinic, Rochester  

Nancy Bartlett, MD  
Washington University Medical School  

Kristie A. Blum, MD  
Winship Cancer Institute of Emory University  

Catherine Bollard, MD, MBChB  
Children’s National Medical Center  
George Washington University  

James Cerhan, MD, PhD  
Mayo Clinic, Rochester  

Ethe1. Cesaran, MD, PhD  
New York-Presbyterian Hospital  
Weill Cornell Medicine  

Bruce D. Cheson, MD, FACP, FAAD, FASCO  
Past Chair, 2010-2012  
Georgetown University Hospital  
Lombardi Comprehensive Cancer Center  

Morton Coleman, MD  
New York-Presbyterian Hospital  
Weill Cornell Medicine  

Sandeep Dave, MD, MS  
Duke University  

Kieron M. Dunleavy, MD  
George Washington University  
GW Cancer Center  

Kojo S.J. Elenitoba-Johnson, MD  
Raymond and Ruth Perelman School of Medicine  
University of Pennsylvania  

Andrew M. Evans, DO, MSc  
Rutgers Cancer Institute  

Christopher R. Flowers, MD, MS  
Winship Cancer Institute of Emory University  

Jonathan W. Friedberg, MD, MMSc  
James P. Wilmot Cancer Institute  
University of Rochester Medical Center  

Leo I. Gordon, MD, FACP  
Imperial Post Chair  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University  

Thomas M. Habermann, MD  
Past Chair, 2017-2019  
Mayo Clinic, Rochester  

Steven M. Horwitz, MD  
Memorial Sloan Kettering Cancer Center  

Eric D. Hsi, MD  
Cleveland Clinic  

Brad S. Kahi, MD  
Washington University Medical School  

Kara Kelly, MD  
Oskhei Children’s Hospital  
University of Buffalo Jacobs School of Medicine  
and Biomedical Sciences  

Ann S. LaCasce, MD  
Harvard Medical School  

Brian K. Link, MD  
University of Iowa  

John P. Leonard, MD  
Past Chair, 2012-2015  
New York-Presbyterian Hospital  
Weill Cornell Medicine  

Izidore S. Lossos, MD  
University of Miami Health System  
Sylvester Comprehensive Cancer Center  

Peter Martin, MD  
Weill Cornell Medicine  

Ari Melnick, MD  
New York-Presbyterian Hospital  
Weill Cornell Medicine  

Lindsay Morton, PhD  
National Cancer Institute  

Owen O’Connor, MD, PhD  
Columbia University Medical Center  

Laura Pasqualucci, MD  
Columbia University  

Herbert Irving Comprehensive Cancer Center  

Barbara Pro, MD  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University  

Kanti R. Rai, MD, BS  
Hofstra Northwell School of Medicine  

Kerry Savage, MD  
British Columbia Cancer  

Laurie Sehn, MD, MPH  
British Columbia Cancer  

Margaret Shipp, MD  
Dana-Farber Cancer Institute  

Eduardo M. Sotomayor, MD  
George Washington University  

GW Cancer Center  

Christian Steidl, MD  
British Columbia Cancer  

John Timmerman, MD  
University of California, Los Angeles, Jonsson Comprehensive Cancer Center  

Sven de Vos, MD, PhD  
University of California, Los Angeles, Jonsson Comprehensive Cancer Center  

David Weinstock, MD  
Dana-Farber Cancer Institute  

Hans-Guido Wendel, MD  
Memorial Sloan Kettering Cancer Center  

Michael E. Williams, MD, ScM  
University of Virginia Cancer Center  

Members Emeritus  

Joseph R. Bertino, MD  
Founding Chair  
Rutgers Robert Wood Johnson Medical School  
The Cancer Institute of New Jersey  

Charles Coltman, MD  
San Antonio Cancer Institute  

Saul Rosenberg, MD  
Stanford University School of Medicine  

About the Research Report

Research Report is a publication of the Lymphoma Research Foundation, providing the latest updates on our grantees and their progress, as well as on the work of the Foundation. The Lymphoma Research Foundation is the nation’s largest non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services.

LRF Helpline

The Lymphoma Research Foundation (LRF) offers a variety of support services to lymphoma patients, survivors, and caregivers. These programs include the LRF Helpline, which provides information about lymphoma and its treatment options, as well as the Lymphoma Support Network for peer support and encouragement. Individuals touched by lymphoma can also learn about novel and emerging therapies through our Clinical Trials Information Service. As part of this program, LRF staff can conduct individualized lymphoma trial searches for patients to assist them in making important decisions about their care. For more information about the Clinical Trials Information Service or any of LRF’s support services, please contact the LRF Helpline at 1-800-500-9976 or helpline@lymphoma.org, or visit lymphoma.org/learn/supportservices.
Lymphoma Research Foundation
Wall Street Plaza
88 Pine Street, Suite 2400
New York, NY 10005

IN THIS ISSUE:

- Oral Therapies Initiative
- Letter from the CEO
- Spring Scientific Workshops
- News from the Field
- Professional Ed Partnership
- Scientific Advisory Board

Scan using your smartphone to read our Research Reports online.

Spring Scientific Workshops
Overviews of the Marginal Zone Lymphoma and Adolescent/Young Adult Lymphoma Scientific Workshops convened by the Foundation.

Visit page 4 for details.

WE RIDE TO CURE LYMPHOMA. JOIN US.

Join Team LRF to help cure lymphoma

Sunday, September 22, 2019
Barnesville School, Barnesville, MD
Lymphoma.org/ResearchRide

50/40/25/10 mile ride options.
All ages 12+ welcome.

Ride Co-founders Dr. Bruce and Christine Cheson

All funds raised will support life changing research and patient programs.